Zacks: Analysts Set $27.33 Price Target for Zealand Pharma A/S (ZEAL)
Shares of Zealand Pharma A/S (NASDAQ:ZEAL) have been assigned an average broker rating score of 1.83 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company.
Analysts have set a 1-year consensus target price of $27.33 for the company and are predicting that the company will post ($0.36) EPS for the current quarter, according to Zacks. Zacks has also given Zealand Pharma A/S an industry rank of 167 out of 265 based on the ratings given to its competitors.
ZEAL has been the topic of a number of recent analyst reports. Goldman Sachs Group, Inc. (The) initiated coverage on Zealand Pharma A/S in a report on Wednesday, September 27th. They set a “buy” rating on the stock. Needham & Company LLC assumed coverage on Zealand Pharma A/S in a report on Tuesday, September 5th. They set a “buy” rating and a $26.00 target price on the stock. Guggenheim assumed coverage on Zealand Pharma A/S in a report on Tuesday, September 5th. They set a “buy” rating and a $28.00 target price on the stock. Finally, Morgan Stanley assumed coverage on Zealand Pharma A/S in a report on Tuesday, September 5th. They set an “overweight” rating and a $28.00 target price on the stock.
Zealand Pharma A/S (ZEAL) opened at $15.10 on Friday.
TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/11/04/zacks-analysts-set-27-33-price-target-for-zealand-pharma-as-zeal.html.
Zealand Pharma A/S Company Profile
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.